Drug intelligence / Profile preview

l-carnitine + eicosapentaenoic acid + medroxyprogesterone + megestrol acetate + thalidomide

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Subcutaneous
01

Overview

This is a combination drug consisting of five active ingredients: - **L-carnitine** is a naturally occurring amino acid derivative involved in energy metabolism and fatty acid transport. - **Eicosapentaenoic acid (EPA)** is an omega-3 fatty acid with anti-inflammatory properties, commonly found in fish oil. - **Medroxyprogesterone** is a synthetic progestin used primarily for hormonal therapy, contraception, and certain cancers. - **Megestrol acetate** is a synthetic progestin used as an appetite stimulant (notably for cachexia/wasting syndromes) and as an antineoplastic agent in breast and endometrial cancer. It acts mainly as an agonist of the progesterone receptor[1][2][3][4][5]. - **Thalidomide** is an immunomodulatory agent with anti-inflammatory and antiangiogenic effects. It inhibits tumor necrosis factor-alpha (TNF-alpha), modulates cytokines such as IL-6, inhibits angiogenesis via basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), and binds to cereblon to degrade transcription factors IKZF1/IKZF3. Thalidomide has been reintroduced for use in multiple myeloma, erythema nodosum leprosum, some skin disorders, HIV-associated wasting syndrome, among others[6][7][9]. This specific five-drug combination does not correspond to any known approved or branded product but may be considered or studied experimentally for severe cachexia/wasting syndromes due to its components' synergistic effects on appetite stimulation, inflammation modulation, hormone replacement/antagonism, immune modulation, or cancer therapy.

02

Targets

PR (Progesterone receptor)GR (Glucocorticoid receptor)CRBN (Cereblon)AR (Adrenergic receptors)

Beyond the preview

Go deeper on l-carnitine + eicosapentaenoic acid + medroxyprogesterone + megestrol acetate + thalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on l-carnitine + eicosapentaenoic acid + medroxyprogesterone + megestrol acetate + thalidomide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call